StreetInsider.com News Articles

Izotropic Signs Letter Agreement for Regional Operations in Africa & the GCC

Wed, 18 Feb 2026 08:00:00 -0500

Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 18, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that it has entered into a Letter Agreement (the "Agreement") with a business group ("BG") to establish an entity named Izotropic Africa (the "Entity") based in Casablanca, Morocco. The Entity is intended to license, market, distribute, and evaluate manufacturing and/or assembly of IzoView Breast CT and certain follow-on products in all of Africa

Izotropic Signs Letter Agreement for Regional Operations in Africa & the GCC

Wed, 18 Feb 2026 08:00:00 -0500

Izotropic completes $300,000 private placement and settles debt

Wed, 04 Feb 2026 08:02:16 -0500

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) completed a non-brokered private placement raising $300,000 and entered into a debt settlement agreement with a lender, according to a company statement.

The medical device company issued 1,200,000 units at $0.25 per unit. Each unit consists of one common share and one transferable warrant that allows the holder to purchase an additional share at $0.25 for three years from the closing date.

The company will use proceeds from the offering for general working capital purposes.

Separately, Izotropic settled $60,000 in accrued interest owed to a lender through the issuance of 240,000 units at $0.25 per

Izotropic Closes Non-Brokered Private Placement and Announces Debt Settlement

Wed, 04 Feb 2026 08:00:00 -0500

Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 4, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that further to its January 28, 2026 announcement it has completed a non-brokered private placement financing (the "Offering"), and that is has entered into a debt settlement agreement (the "Agreement") with a lender (the "Lender") to settle outstanding interest payable pursuant to a promissory note originally issued by the Company.

In connection with

Izotropic Closes Non-Brokered Private Placement and Announces Debt Settlement

Wed, 04 Feb 2026 08:00:00 -0500

In connection with

Izotropic announces $300,000 private placement for working capital

Wed, 28 Jan 2026 08:02:22 -0500

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) announced plans for a non-brokered private placement to raise up to $300,000 for general working capital.

The medical device company plans to issue 1.2 million units at $0.25 each. Each unit consists of one common share and one transferable warrant, with warrants exercisable at $0.25 per share for three years from closing.

Izotropic develops imaging-based products for breast cancer screening, diagnosis and treatment. The company said its primary objective remains securing capital financing to fund commercialization of its IzoView Breast CT system while evaluating non-dilutive funding options.

The company reported it continues evaluating strategic relationships

Izotropic Provides Corporate Update & Announces Non-Brokered Private Placement

Wed, 28 Jan 2026 08:00:00 -0500

Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - January 28, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, provides a corporate update and announces the intention to complete a small non-brokered private placement financing.

The Company's primary objective is securing capital financing to fund the commercialization of IzoView Breast CT, including prioritizing non-dilutive options, while actively evaluating opportunities to expedite additional regulatory pathways and positioning for earlier revenue generation.

These efforts may

Izotropic Provides Corporate Update & Announces Non-Brokered Private Placement

Wed, 28 Jan 2026 08:00:00 -0500

These efforts may

Izotropic Announces AGM Results

Wed, 31 Dec 2025 16:31:00 -0500

Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - December 31, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the results of its Annual General and Special Meeting held on December 29, 2025.

Company matters submitted to shareholders for approval as set out in the Company's Notice of Meeting and Management Information Circular, dated November 27, 2025, were approved by the requisite majority of votes cast at the meeting.

The primary

Izotropic Announces AGM Results

Wed, 31 Dec 2025 16:31:00 -0500

The primary

Izotropic Launches Podcast Episode #2: AI and the Future of Breast Imaging: How Izotropic is Leading the Innovation

Wed, 12 Nov 2025 08:00:00 -0500

Vancouver, British Columbia, and Sacramento, California--(Newsfile Corp. - November 12, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the release of the second episode in its podcast series: AI and the Future of Breast Imaging: How Izotropic is Leading the Innovation is now available in English, Arabic, Chinese, French, German, Italian and Spanish.

Building on the foundation set in Episode 1, which explored

Izotropic Launches Podcast Episode #2: AI and the Future of Breast Imaging: How Izotropic is Leading the Innovation

Wed, 12 Nov 2025 08:00:00 -0500

Building on the foundation set in Episode 1, which explored

Izotropic Launches "Breast Imaging News" Page on BreastCT.com

Tue, 28 Oct 2025 08:00:00 -0500

Vancouver, British Columbia, and Sacramento, California--(Newsfile Corp. - October 28, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, is pleased to announce the launch of the "Breast Imaging News" section on BreastCT.com - a timely and strategic addition to the Company's educational and awareness website.

This new page provides regular and curated coverage of key events across the breast imaging landscape, including clinical trials, peer-reviewed studies, mergers & acquisitions, and

Izotropic Launches "Breast Imaging News" Page on BreastCT.com

Tue, 28 Oct 2025 08:00:00 -0500

This new page provides regular and curated coverage of key events across the breast imaging landscape, including clinical trials, peer-reviewed studies, mergers & acquisitions, and

Izotropic Corporation’s (CSE: IZO) (OTCQB: IZOZF) Leverages AI with Next-Gen Breast CT Imaging System